AR029402A1 - Cristales de inhibidores del intercambiador de sodio-hidrogeno tipo 1, su preparacion, su uso en la fabricacion de medicamentos y composiciones farmaceuticas que los contiene - Google Patents

Cristales de inhibidores del intercambiador de sodio-hidrogeno tipo 1, su preparacion, su uso en la fabricacion de medicamentos y composiciones farmaceuticas que los contiene

Info

Publication number
AR029402A1
AR029402A1 ARP000105700A ARP000105700A AR029402A1 AR 029402 A1 AR029402 A1 AR 029402A1 AR P000105700 A ARP000105700 A AR P000105700A AR P000105700 A ARP000105700 A AR P000105700A AR 029402 A1 AR029402 A1 AR 029402A1
Authority
AR
Argentina
Prior art keywords
crystals
preparation
compositions containing
inhibitors
sodium
Prior art date
Application number
ARP000105700A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR029402A1 publication Critical patent/AR029402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cristales inhibidores del NHE-1, procedimientos de uso de tales cristales inhibidores del NHE-1, procedimiento para su preparacion y composiciones farmacéuticas que contiene tales cristales inhibidores del NHE-1. Los cristales inhibidores del NHE-1 son utiles para reducir la lesion en los tejidos originada por una isquemia en los tejidos.
ARP000105700A 1999-10-29 2000-10-27 Cristales de inhibidores del intercambiador de sodio-hidrogeno tipo 1, su preparacion, su uso en la fabricacion de medicamentos y composiciones farmaceuticas que los contiene AR029402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
AR029402A1 true AR029402A1 (es) 2003-06-25

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105700A AR029402A1 (es) 1999-10-29 2000-10-27 Cristales de inhibidores del intercambiador de sodio-hidrogeno tipo 1, su preparacion, su uso en la fabricacion de medicamentos y composiciones farmaceuticas que los contiene

Country Status (44)

Country Link
EP (1) EP1224179B1 (es)
JP (1) JP2003512455A (es)
KR (1) KR100464526B1 (es)
CN (2) CN1205205C (es)
AP (1) AP2002002493A0 (es)
AR (1) AR029402A1 (es)
AT (1) ATE271047T1 (es)
AU (1) AU778573B2 (es)
BG (1) BG106729A (es)
BR (1) BR0015275A (es)
CA (1) CA2389020A1 (es)
CO (1) CO5271714A1 (es)
CZ (1) CZ20021332A3 (es)
DE (1) DE60012208T2 (es)
DK (1) DK1224179T3 (es)
DZ (1) DZ3463A1 (es)
EA (1) EA004937B1 (es)
EE (1) EE200200227A (es)
ES (1) ES2222923T3 (es)
GE (1) GEP20043222B (es)
GT (1) GT200000180A (es)
HK (1) HK1048472B (es)
HR (1) HRP20020366B1 (es)
HU (1) HUP0204009A3 (es)
IL (1) IL148581A0 (es)
IS (1) IS6302A (es)
MA (1) MA26840A1 (es)
MX (1) MXPA02004358A (es)
NO (1) NO20021821L (es)
NZ (1) NZ517738A (es)
OA (1) OA12080A (es)
PA (1) PA8505501A1 (es)
PE (1) PE20010764A1 (es)
PL (1) PL354869A1 (es)
PT (1) PT1224179E (es)
SI (1) SI1224179T1 (es)
SK (1) SK5312002A3 (es)
SV (1) SV2002000209A (es)
TN (1) TNSN00210A1 (es)
TR (1) TR200201167T2 (es)
UA (1) UA72002C2 (es)
WO (1) WO2001030759A2 (es)
YU (1) YU31502A (es)
ZA (1) ZA200203295B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
EP1355899A1 (en) * 2001-01-31 2003-10-29 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
MXPA04006615A (es) * 2002-01-30 2004-10-04 Pfizer Prod Inc Composiciones farmaceuticas de mesilato de zoniporida y procedimientos para mejorar la solubilidad de la zoniporida.
BR0309707A (pt) * 2002-05-02 2005-02-09 Pfizer Prod Inc Tratamento de diabetes e complicações diabéticas com inibidores nhe-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454902A1 (en) * 1998-02-27 2004-09-08 Pfizer Products Inc. N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia

Also Published As

Publication number Publication date
DK1224179T3 (da) 2004-10-25
AP2002002493A0 (en) 2002-06-30
KR100464526B1 (ko) 2005-01-03
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12
UA72002C2 (en) 2005-01-17
SI1224179T1 (en) 2004-10-31
TR200201167T2 (tr) 2002-08-21
ZA200203295B (en) 2003-06-25
HK1048472B (zh) 2005-09-16
DZ3463A1 (fr) 2001-05-03
MXPA02004358A (es) 2002-11-07
OA12080A (en) 2003-08-25
CN1636991A (zh) 2005-07-13
HUP0204009A3 (en) 2004-07-28
IS6302A (is) 2002-03-15
AU7441500A (en) 2001-05-08
WO2001030759A2 (en) 2001-05-03
HUP0204009A2 (hu) 2003-03-28
HRP20020366B1 (en) 2005-04-30
BR0015275A (pt) 2002-07-16
SV2002000209A (es) 2002-07-16
ES2222923T3 (es) 2005-02-16
PT1224179E (pt) 2004-10-29
GEP20043222B (en) 2004-04-26
EA004937B1 (ru) 2004-10-28
DE60012208T2 (de) 2005-07-21
TNSN00210A1 (fr) 2005-11-10
CO5271714A1 (es) 2003-04-30
EP1224179B1 (en) 2004-07-14
CN1384829A (zh) 2002-12-11
CA2389020A1 (en) 2001-05-03
PL354869A1 (en) 2004-03-08
AU778573B2 (en) 2004-12-09
EE200200227A (et) 2003-06-16
MA26840A1 (fr) 2004-12-20
JP2003512455A (ja) 2003-04-02
NO20021821D0 (no) 2002-04-18
HK1048472A1 (en) 2003-04-04
EA200200416A1 (ru) 2002-10-31
BG106729A (bg) 2002-12-29
PE20010764A1 (es) 2001-07-23
HRP20020366A2 (en) 2004-02-29
CZ20021332A3 (cs) 2002-10-16
GT200000180A (es) 2002-04-11
PA8505501A1 (es) 2003-09-05
DE60012208D1 (de) 2004-08-19
SK5312002A3 (en) 2003-01-09
KR20020040918A (ko) 2002-05-30
WO2001030759A3 (en) 2001-09-13
NO20021821L (no) 2002-04-18
CN1205205C (zh) 2005-06-08
NZ517738A (en) 2005-06-24
YU31502A (sh) 2004-12-31
EP1224179A2 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ES2196377T3 (es) Derivados de naftiridina.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
SV2008001369A (es) Benzimidazoles
AR024138A1 (es) Inhibidores de la proliferacion celular
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
AR007040A1 (es) Compuestos de eritromicina 6-0-sustituida, composiciones farmaceuticas, uso de dichos compuestos para preparar medicamentos y procedimiento para supreparacion
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ES2165586T3 (es) Derivados de isatina como inhibidores de acetilcolinesterasa y analgesicos.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
AR029402A1 (es) Cristales de inhibidores del intercambiador de sodio-hidrogeno tipo 1, su preparacion, su uso en la fabricacion de medicamentos y composiciones farmaceuticas que los contiene
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.

Legal Events

Date Code Title Description
FB Suspension of granting procedure